《2020中国心脏骤停后脑保护专家共识》解读三：药物治疗

2021-12-01 中华脑血管病杂志(电子版)

为了减轻脑损伤,改善心脏骤停患者的存活率和神经功能预后,本文就《2020中国心脏骤停后脑保护专家共识》中的药物治疗部分进行解读,内容主要涉及脑保护的治疗方法和药物治疗选择。

中文标题：

发布机构：

发布日期：

2021-12-01

简要介绍：

脑保护治疗是心脏骤停患者心肺复苏成功并获得良好预后的关键措施之一。尽管心肺复苏救治成功率在提升,但由于心肺复苏后续治疗不足,心脏骤停患者心肺复苏后的预后并未得到明显改善。为了减轻脑损伤,改善心脏骤停患者的存活率和神经功能预后,本文就《2020中国心脏骤停后脑保护专家共识》中的药物治疗部分进行解读,内容主要涉及脑保护的治疗方法和药物治疗选择。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=d9ee31c002326304, title=《2020中国心脏骤停后脑保护专家共识》解读三：药物治疗, enTitle=, guiderFrom=中华脑血管病杂志(电子版), authorId=0, author=, summary=为了减轻脑损伤,改善心脏骤停患者的存活率和神经功能预后,本文就《2020中国心脏骤停后脑保护专家共识》中的药物治疗部分进行解读,内容主要涉及脑保护的治疗方法和药物治疗选择。 , cover=https://img.medsci.cn/2022118/1642516460453_5579292.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Dec 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">脑保护治疗是心脏骤停患者心肺复苏成功并获得良好预后的关键措施之一。尽管心肺复苏救治成功率在提升,但由于心肺复苏后续治疗不足,心脏骤停患者心肺复苏后的预后并未得到明显改善。为了减轻脑损伤,改善心脏骤停患者的存活率和神经功能预后,本文就《2020中国心脏骤停后脑保护专家共识》中的药物治疗部分进行解读,内容主要涉及脑保护的治疗方法和药物治疗选择。 </span></p>, tagList=[TagDto(tagId=70, tagName=心肺复苏), TagDto(tagId=885, tagName=心脏骤停), TagDto(tagId=1113, tagName=药物治疗), TagDto(tagId=47636, tagName=脑保护)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4401, appHits=101, showAppHits=0, pcHits=628, showPcHits=4300, likes=0, shares=14, comments=5, approvalStatus=1, publishedTime=Tue Jan 18 22:32:46 CST 2022, publishedTimeString=2021-12-01, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Jan 18 22:36:19 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Fri Jan 05 20:53:21 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《2020中国心脏骤停后脑保护专家共识》解读三：药物治疗.pdf)])

《2020中国心脏骤停后脑保护专家共识》解读三：药物治疗.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1193896, encodeId=20cf1193896ac, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:54:56 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193234, encodeId=4f9811932342a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10105725125, createdName=ms1000001656413688, createdTime=Mon Feb 14 10:18:39 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187577, encodeId=e42c118e57708, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Mon Jan 24 05:53:50 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185893, encodeId=d5bb1185893c6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=335a6443017, createdName=ms1000001753074234, createdTime=Wed Jan 19 07:55:00 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185875, encodeId=f3ca11858e5bb, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 19 07:29:29 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
2022-02-16 龙珠

学习好资料

47 0
[GetPortalCommentsPageByObjectIdResponse(id=1193896, encodeId=20cf1193896ac, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:54:56 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193234, encodeId=4f9811932342a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10105725125, createdName=ms1000001656413688, createdTime=Mon Feb 14 10:18:39 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187577, encodeId=e42c118e57708, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Mon Jan 24 05:53:50 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185893, encodeId=d5bb1185893c6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=335a6443017, createdName=ms1000001753074234, createdTime=Wed Jan 19 07:55:00 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185875, encodeId=f3ca11858e5bb, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 19 07:29:29 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
2022-02-14 ms1000001656413688

学习

47 0
[GetPortalCommentsPageByObjectIdResponse(id=1193896, encodeId=20cf1193896ac, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:54:56 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193234, encodeId=4f9811932342a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10105725125, createdName=ms1000001656413688, createdTime=Mon Feb 14 10:18:39 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187577, encodeId=e42c118e57708, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Mon Jan 24 05:53:50 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185893, encodeId=d5bb1185893c6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=335a6443017, createdName=ms1000001753074234, createdTime=Wed Jan 19 07:55:00 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185875, encodeId=f3ca11858e5bb, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 19 07:29:29 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
2022-01-24 forvalen

好好学习

62 0
[GetPortalCommentsPageByObjectIdResponse(id=1193896, encodeId=20cf1193896ac, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:54:56 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193234, encodeId=4f9811932342a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10105725125, createdName=ms1000001656413688, createdTime=Mon Feb 14 10:18:39 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187577, encodeId=e42c118e57708, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Mon Jan 24 05:53:50 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185893, encodeId=d5bb1185893c6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=335a6443017, createdName=ms1000001753074234, createdTime=Wed Jan 19 07:55:00 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185875, encodeId=f3ca11858e5bb, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 19 07:29:29 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
2022-01-19 ms1000001753074234

学习学习

61 0
[GetPortalCommentsPageByObjectIdResponse(id=1193896, encodeId=20cf1193896ac, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:54:56 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193234, encodeId=4f9811932342a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10105725125, createdName=ms1000001656413688, createdTime=Mon Feb 14 10:18:39 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187577, encodeId=e42c118e57708, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Mon Jan 24 05:53:50 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185893, encodeId=d5bb1185893c6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=335a6443017, createdName=ms1000001753074234, createdTime=Wed Jan 19 07:55:00 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185875, encodeId=f3ca11858e5bb, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Jan 19 07:29:29 CST 2022, time=2022-01-19, status=1, ipAttribution=)]
2022-01-19 微探

学习学习

59 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

《2020中国心脏骤停后脑保护专家共识》解读三：药物治疗

相关指南

科室

工具

服务